4P-Pharma, a biotechnology company specialised in the sourcing and the development of early stage therapeutic molecules, announced the appointment of Sonia Escaich, PhD, as Chief Operating Officer. “Sonia has deep domain expertise from both drug development and business perspective, she will bring a wealth of experience to the team”, said Revital Rattenbach, Founder and President&hellip
4P-Pharma, a biotechnology company specialised in the sourcing and the development of early stage therapeutic molecules, announces the appointment of Patrice Denèfle, PhD, HDR, Adjunct Prof., as its Chief Scientific Officer (CSO). “We are delighted to welcome Patrice to our team as Chief Scientific Officer. […] I look forward to work closely with him to&hellip
Roselina Lam, our Business Development and Licensing Manager, will attend the upcoming BIO Europe Spring on March 23rd-25th, 2020 in Paris, France. Contact her via the partnering platform or by e-mail, to learn more about our pipeline and discuss future partnerships. She is looking forward to meet you there!
4P-Pharma received the Seal of Excellence from the European Commission for its application related to the development of a disease modifier treatment for osteoarthritis, 4P-004 to the Horizon 2020 EIC Accelerator (SME instrument). Following evaluation by an international panel of independent experts, 4P-Pharma’s project was scored as a high-quality proposal in this highly competitive evaluation&hellip
A poster on 4P-004 entitled “Protective Effects Of Intra-Articular Formulated Liraglutide In Osteoarthritis” (#1970) will be presented during the 2nd Therapeutic Discoveries from Bench to First in Human Clinical Trials Conference, in Riyadh, Saudi Arabia, February 25th -27th, 2020.
4P-Pharma’s CEO, Revital Rattenbach, will attend the upcoming Biotech Showcase 2020 in San Francisco (USA), January 13th-15th, 2020. Contact us via the partnering platform or by e-mail to schedule a meeting and discuss future collaborations.